Breast cancer is the most common malignancy among women worldwide [1], and patients with metastatic or recurrent human epidermal growth factor 2 (HER2)-negative breast cancer have a poor prognosis, especially if they have previously received anthracycline or taxane treatment. This evidence concerns the gene ERBB2 and breast carcinoma.